Fox Run Management L.L.C. Sells 10,710 Shares of Haemonetics Corporation $HAE

Posted by on Jun 9th, 2026

Fox Run Management L.L.C. cut its holdings in shares of Haemonetics Corporation (NYSE:HAE – Free Report) by 38.4% during the 4th quarter, Holdings Channel reports. The firm owned 17,151 shares of the medical instruments supplier’s stock after selling 10,710 shares during the period. Fox Run Management L.L.C.’s holdings in Haemonetics were worth $1,375,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Isthmus Partners LLC increased its holdings in shares of Haemonetics by 36.5% during the third quarter. Isthmus Partners LLC now owns 61,702 shares of the medical instruments supplier’s stock worth $3,007,000 after purchasing an additional 16,505 shares during the period. Invenomic Capital Management LP increased its holdings in shares of Haemonetics by 1,691.5% during the third quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock worth $24,288,000 after purchasing an additional 470,502 shares during the period. Skylands Capital LLC increased its holdings in shares of Haemonetics by 195.4% during the third quarter. Skylands Capital LLC now owns 81,369 shares of the medical instruments supplier’s stock worth $3,966,000 after purchasing an additional 53,819 shares during the period. Barrow Hanley Mewhinney & Strauss LLC increased its holdings in shares of Haemonetics by 16.5% during the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 559,972 shares of the medical instruments supplier’s stock worth $27,293,000 after purchasing an additional 79,138 shares during the period. Finally, William Blair Investment Management LLC increased its stake in Haemonetics by 13.7% in the third quarter. William Blair Investment Management LLC now owns 476,710 shares of the medical instruments supplier’s stock valued at $23,235,000 after acquiring an additional 57,332 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Haemonetics Stock Performance

Shares of NYSE:HAE opened at $75.15 on Tuesday. The company’s 50 day simple moving average is $60.39 and its 200 day simple moving average is $67.22. The stock has a market capitalization of $3.42 billion, a price-to-earnings ratio of 37.20, a price-to-earnings-growth ratio of 1.43 and a beta of 0.55. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32.

Haemonetics (NYSE:HAE – Get Free Report) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The firm had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. During the same quarter last year, the business posted $1.24 earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, research analysts predict that Haemonetics Corporation will post 5.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on HAE shares. Citigroup lifted their price objective on shares of Haemonetics from $64.00 to $70.00 and gave the company a “neutral” rating in a research note on Thursday, May 28th. JPMorgan Chase & Co. decreased their price objective on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. Barrington Research decreased their price objective on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings cut shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, May 21st. Finally, Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $77.11.

Get Our Latest Stock Analysis on Haemonetics

Haemonetics Profile

(Free Report)

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

Featured Articles

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE – Free Report).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.